Icon

BioLineRx Ltd Stock Analysis and Price Target COMMON STOCK | Biotechnology | NSD

stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Neutral

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 1.43

-0.03 (-2.05)%

USD 0.12B

0.50M

USD 21.00(+1,368.53%)

N/A

Icon

BLRX

BioLineRx Ltd (USD)
COMMON STOCK | NSD
USD 1.4300
-0.03 (-2.05%)
At close: 04:00PM EST
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Neutral

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.12B

N/A

USD 1.43

BioLineRx Ltd Stock Forecast

Show ratings and price targets of :
USD 21.00
(+1,368.53%)

Based on the BioLineRx Ltd stock forecast from 1 analysts, the average analyst target price for BioLineRx Ltd is USD 21.00 over the next 12 months. BioLineRx Ltd’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of BioLineRx Ltd is Neutral, which is based on 4 positive signals and 4 negative signals. At the last closing, BioLineRx Ltd’s stock price was USD 1.43. BioLineRx Ltd’s stock price has changed by -5.92% over the past week, +9.16% over the past month and +104.29% over the last year.

No recent analyst target price found for BioLineRx Ltd
No recent average analyst rating found for BioLineRx Ltd

Company Overview BioLineRx Ltd

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment ...Read More

https://www.biolinerx.com

Modi?in Technology Park, Hevel Modi'in, Israel, 7177871

49

December

USD

USA

Adjusted Closing Price for BioLineRx Ltd (BLRX)

Loading...

Unadjusted Closing Price for BioLineRx Ltd (BLRX)

Loading...

Share Trading Volume for BioLineRx Ltd Shares

Loading...

Compare Performance of BioLineRx Ltd Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for BLRX

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To BioLineRx Ltd (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc -3.15 (-0.90%) USD91.42B 26.68 16.84

ETFs Containing BLRX

Symbol Name BLRX's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About BioLineRx Ltd (BLRX) Stock

Based on ratings from 1 analysts BioLineRx Ltd's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 1 buy, sell and hold ratings.

Unfortunately we do not have enough data on BLRX's stock to indicate if its a good dividend stock.

Based on targets from 1 analysts, the average taret price for BLRX is USD 21.00 over the next 12 months. The maximum analyst target price is USD 21 while the minimum anlayst target price is USD 21.

Unfortunately we do not have enough data on BLRX's stock to indicate if its overvalued.

The last closing price of BLRX's stock was USD 1.43.

The most recent market capitalization for BLRX is USD 0.12B.

Based on targets from 1 analysts, the average taret price for BLRX is projected at USD 21.00 over the next 12 months. This means that BLRX's stock price may go up by +1,368.53% over the next 12 months.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...